李全忠, 张才丽. 头孢噻肟在实验性糖尿病鼠的药代动力学和药效学研究J. 药学学报, 1995, 30(7): 495-499.
引用本文: 李全忠, 张才丽. 头孢噻肟在实验性糖尿病鼠的药代动力学和药效学研究J. 药学学报, 1995, 30(7): 495-499.
QZ Li, CL Zhang. THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CEFOTAXIME IN EXPERIMENTAL DIABETIC RATSJ. Acta Pharmaceutica Sinica, 1995, 30(7): 495-499.
Citation: QZ Li, CL Zhang. THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CEFOTAXIME IN EXPERIMENTAL DIABETIC RATSJ. Acta Pharmaceutica Sinica, 1995, 30(7): 495-499.

头孢噻肟在实验性糖尿病鼠的药代动力学和药效学研究

THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CEFOTAXIME IN EXPERIMENTAL DIABETIC RATS

  • 摘要: 用四氧嘧啶(alloxan)引起的大鼠糖尿病模型,观察糖尿病早期对头孢噻肟(CTX)药代动力学和药效学的影响。HPLC方法测定CTX的血药浓度,用计算机计算各项药代参数。糖尿病组动物的血药峰浓度和AUC值明显低于对照组,但两组的T1/2ka和T<>/i>1/2ke无明显差别,提示糖尿病早期不影响CTX的吸收和消除速度。但由于CTX的蛋白结合率降低,游离药物浓度增加,大量游离药物进入组织液,可使血中药物总浓度降低。CTX对两组动物肺炎球菌感染的PD50无明显差别,可能与糖尿病大鼠血中游离的药浓度提高有关。

     

    Abstract: The present paper describes the pharmacokindtics and pharmacodynamics of CTX in both normal control rats and early alloxan-diabetic rats in vivo. The plasma concentrations of CTX were determined with HPLC. The main pharmacokinetic parameters of the two groups were calculated with computer.Compared with the control group, t冰Cand AUC in the diabetic group decreased significantly. Most of the free drug was distributed to tissue fluid because the protein binding of CTX decreased. But ,the T1/2 ka and T1/2 ke of the two groups were not significantly different. It was suggested that the absorption and elimination rate of CTX were not affected in early diabetic rats. The PD50 of CTX against S. Pneumonias infection was not different significantly between the two groups.This implies that the therapeutic effect of CTX was enhanced as the plasma free concentration could be increased in diabetic ratts.